Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three
years will reduce vision loss associated with diabetic retinopathy.